125 related articles for article (PubMed ID: 33073205)
1. Development of gemcitabine-resistant patient-derived xenograft models of pancreatic ductal adenocarcinoma.
Miller AL; Garcia PL; Gamblin TL; Vance RB; Yoon KJ
Cancer Drug Resist; 2020; 3(3):572-585. PubMed ID: 33073205
[TBL] [Abstract][Full Text] [Related]
2. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
[TBL] [Abstract][Full Text] [Related]
3. Human equilibrative nucleoside transporter-1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression; do they have survival impact to pancreatic cancer?
Hwang DW; Shin E; Cho JY; Han HS; Yoon YS
Ann Hepatobiliary Pancreat Surg; 2020 May; 24(2):127-136. PubMed ID: 32457256
[TBL] [Abstract][Full Text] [Related]
4. The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.
Skrypek N; Duchêne B; Hebbar M; Leteurtre E; van Seuningen I; Jonckheere N
Oncogene; 2013 Mar; 32(13):1714-23. PubMed ID: 22580602
[TBL] [Abstract][Full Text] [Related]
5. BET inhibition decreases HMGCS2 and sensitizes resistant pancreatic tumors to gemcitabine.
Miller AL; Fehling SC; Vance RB; Chen D; Brown EJ; Hossain MI; Heard EO; Andrabi SA; Wang H; Yang ES; Buchsbaum DJ; van Waardenburg RCAM; Bellis SL; Yoon KJ
Cancer Lett; 2024 Jun; 592():216919. PubMed ID: 38704133
[TBL] [Abstract][Full Text] [Related]
6. In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
Bergman AM; Eijk PP; Ruiz van Haperen VW; Smid K; Veerman G; Hubeek I; van den Ijssel P; Ylstra B; Peters GJ
Cancer Res; 2005 Oct; 65(20):9510-6. PubMed ID: 16230416
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast growth factor receptor 1 inhibition suppresses pancreatic cancer chemoresistance and chemotherapy-driven aggressiveness.
Lin Q; Serratore A; Niu J; Shen S; Roy Chaudhuri T; Ma WW; Qu J; Kandel ES; Straubinger RM
Drug Resist Updat; 2024 Mar; 73():101064. PubMed ID: 38387284
[TBL] [Abstract][Full Text] [Related]
8. Comparative Proteomic Analysis Identifies Key Metabolic Regulators of Gemcitabine Resistance in Pancreatic Cancer.
Lin Q; Shen S; Qian Z; Rasam SS; Serratore A; Jusko WJ; Kandel ES; Qu J; Straubinger RM
Mol Cell Proteomics; 2022 Oct; 21(10):100409. PubMed ID: 36084875
[TBL] [Abstract][Full Text] [Related]
9. Disrupted plasma membrane localization of equilibrative nucleoside transporter 2 in the chemoresistance of human pancreatic cells to gemcitabine (dFdCyd).
Nishio R; Tsuchiya H; Yasui T; Matsuura S; Kanki K; Kurimasa A; Hisatome I; Shiota G
Cancer Sci; 2011 Mar; 102(3):622-9. PubMed ID: 21205085
[TBL] [Abstract][Full Text] [Related]
10. Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.
Fisher SB; Fisher KE; Patel SH; Lim MG; Kooby DA; El-Rayes BF; Staley CA; Adsay NV; Farris AB; Maithel SK
Cancer; 2013 Jan; 119(2):454-62. PubMed ID: 22760605
[TBL] [Abstract][Full Text] [Related]
11. Expression of fibroblast growth factor receptor 1 correlates inversely with the efficacy of single-agent fibroblast growth factor receptor-specific inhibitors in pancreatic cancer.
Lin Q; Serratore A; Perri J; Roy Chaudhuri T; Qu J; Ma WW; Kandel ES; Straubinger RM
Br J Pharmacol; 2024 May; 181(9):1383-1403. PubMed ID: 37994108
[TBL] [Abstract][Full Text] [Related]
12. Bexarotene (LGD1069, Targretin), a selective retinoid X receptor agonist, prevents and reverses gemcitabine resistance in NSCLC cells by modulating gene amplification.
Tooker P; Yen WC; Ng SC; Negro-Vilar A; Hermann TW
Cancer Res; 2007 May; 67(9):4425-33. PubMed ID: 17483357
[TBL] [Abstract][Full Text] [Related]
13. Synergistic Pharmacodynamic Effects of Gemcitabine and Fibroblast Growth Factor Receptor Inhibitors on Pancreatic Cancer Cell Cycle Kinetics and Proliferation.
Lin Q; Qian Z; Jusko WJ; Mager DE; Ma WW; Straubinger RM
J Pharmacol Exp Ther; 2021 Jun; 377(3):370-384. PubMed ID: 33753538
[TBL] [Abstract][Full Text] [Related]
14. Precision Medicine and Pancreatic Cancer: A Gemcitabine Pathway Approach.
Farrell JJ; Moughan J; Wong JL; Regine WF; Schaefer P; Benson AB; Macdonald JS; Liu X; Yen Y; Lai R; Zheng Z; Bepler G; Guha C; Elsaleh H
Pancreas; 2016 Nov; 45(10):1485-1493. PubMed ID: 27748721
[TBL] [Abstract][Full Text] [Related]
15. Precision design of nanomedicines to restore gemcitabine chemosensitivity for personalized pancreatic ductal adenocarcinoma treatment.
Zhao X; Wang X; Sun W; Cheng K; Qin H; Han X; Lin Y; Wang Y; Lang J; Zhao R; Zheng X; Zhao Y; Shi J; Hao J; Miao QR; Nie G; Ren H
Biomaterials; 2018 Mar; 158():44-55. PubMed ID: 29275122
[TBL] [Abstract][Full Text] [Related]
16. RRM1 Expression as a Prognostic Biomarker for Unresectable or Recurrent Biliary Tract Cancer Treated with Gemcitabine plus Cisplatin.
Chun JW; Lee B; Park WS; Han N; Hong EK; Park EY; Han SS; Park SJ; Kim TH; Lee WJ; Woo SM
J Clin Med; 2021 Oct; 10(20):. PubMed ID: 34682775
[TBL] [Abstract][Full Text] [Related]
17. Role of hepatocyte nuclear factor 4 alpha in cell proliferation and gemcitabine resistance in pancreatic adenocarcinoma.
Sun Q; Xu W; Ji S; Qin Y; Liu W; Hu Q; Zhang Z; Liu M; Yu X; Xu X
Cancer Cell Int; 2019; 19():49. PubMed ID: 30867652
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine sensitivity factors, hENT1 and RRM1 as potential prognostic biomarker for advanced biliary tract cancer.
Deng T; Pan H; Han R; Huang D; Li H; Zhou L; Wang X; Bai M; Li X; Liu R; Ge S; Ning T; Zhang L; Ba Y
Int J Clin Exp Med; 2014; 7(12):5041-9. PubMed ID: 25664003
[TBL] [Abstract][Full Text] [Related]
19. Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.
Chung WG; Sandoval MA; Sloat BR; Lansakara-P DS; Cui Z
J Control Release; 2012 Jan; 157(1):132-40. PubMed ID: 21851843
[TBL] [Abstract][Full Text] [Related]
20. Establishment and characterization of the gemcitabine-resistant human gallbladder cancer cell line NOZ GemR.
Xu M; Xu S; Jiang B; Man Z
Ann Med Surg (Lond); 2024 Mar; 86(3):1396-1400. PubMed ID: 38463071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
